EUVIMEDEUVIMED entdecken
Multizentrische Studie

Magnetic Resonance Imaging–Detected High-Risk Markers in Rectal Cancer Patients With a Pathologic Complete Response After Neoadjuvant Therapy

Ke Zhao iD, Minning Zhao, Qing-Yang Li, Jing Yang, Lili Feng, Xiaomei Wu iD, Zhenhui Li, Yanfen Cui, Xinjuan Fan, Ying-Shi Sun iD, Zaiyi Liu iD

JCO Precision Oncology · 2025

DOI: 10.1200/po-25-00357 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Ke Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Chin…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Magnetic Resonance Imaging, Neoadjuvant Therapy. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Pathologic complete response (pCR) is a surrogate end point for prognosis in rectal cancer, yet a subset of pCR patients still face recurrence or poor outcomes. The identification of high-risk pCR patients and the effectiveness of adjuvant therapy remain contentious. This study aimed to evaluate pretreatment magnetic resonance imaging (MRI) markers, identify high-risk pCR patients, and assess the benefit of adjuvant therapy. MATERIALS AND METHODS This retrospective multicenter study analyzed 384 pCR patients (2010-2019) to assess pretreatment MRI markers' prognostic value. Disease-free survival (DFS) and overall survival (OS) were estimated using Kaplan-Meier curves, with group differences evaluated via the log-rank test. RESULTS Among the MRI markers evaluated, magnetic resonance with tumor deposits (mrTD) emerged as the strongest prognostic factor. Positive mrTD was associated with a five-fold increased risk of recurrence (adjusted hazard ratio, 5.16 [95% CI, 2.67 to 9.97]; P < .001) and significantly reduced OS (5.04 [1.80 to 14.1]; P = .002). Patients with mrTD + had a 3-year DFS of 74.5% and a 5-year OS of 83.6%, compared with 96.6% and 98.6%, respectively, in mrTD − patients. Notably, adjuvant therapy did not improve prognosis in pCR patients, regardless of their MRI marker status. CONCLUSION Positive mrTD is a critical prognostic marker in pCR patients. Adjuvant therapy did not confer benefits, highlighting the need for personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsMagnetic Resonance ImagingNeoadjuvant TherapyHumansMaleFemaleMiddle AgedRetrospective StudiesAgedPrognosisAdultDisease-Free SurvivalPathologic Complete Response

Autor:innen und Institutionen

  • Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, China.
  • Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Department of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Gastroenterology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: Ke Zhao, Xiaomei Wu, Ying-Shi Sun, Zaiyi Liu

Zitieren

APA

Zhao, K., Zhao, M., Li, Q. Y., Yang, J., Feng, L., Wu, X., Li, Z., Cui, Y., Fan, X., Sun, Y. S., & Liu, Z. (2025). Magnetic Resonance Imaging–Detected High-Risk Markers in Rectal Cancer Patients With a Pathologic Complete Response After Neoadjuvant Therapy. JCO Precision Oncology. https://doi.org/10.1200/po-25-00357

Vancouver

Zhao K, Zhao M, Li QY, Yang J, Feng L, Wu X, et al. Magnetic Resonance Imaging–Detected High-Risk Markers in Rectal Cancer Patients With a Pathologic Complete Response After Neoadjuvant Therapy. JCO Precision Oncology. 2025. doi:10.1200/po-25-00357

BibTeX
@article{Zhao2025,
  author = {Zhao, Ke and Zhao, Minning and Li, Qing-Yang and Yang, Jing and Feng, Lili and Wu, Xiaomei and Li, Zhenhui and Cui, Yanfen and Fan, Xinjuan and Sun, Ying-Shi and Liu, Zaiyi},
  title = {Magnetic Resonance Imaging–Detected High-Risk Markers in Rectal Cancer Patients With a Pathologic Complete Response After Neoadjuvant Therapy},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-25-00357}
}
Kostenlos starten →